Predictors of survival in stage IV metastatic colorectal cancer

Anticancer Research

Volumn 30, Issue 2, 2010, Pages 653-660

  Zacharakis, Michalis ^a   Xynos, Ioannis D ^a   Lazaris, Andreas ^a   Smaro, Tsaousi ^a   Kosmas, Christos ^b   Dokou, Anna ^a   Felekouras, Evangelos ^a   Antoniou, Efstathios ^a   Polyzos, Aris ^a   Sarantonis, John ^a   Syrios, John ^a   Zografos, George ^c   Papalambros, Alexandros ^a   Tsavaris, Nikolas ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b METAXA CANCER HOSPITAL   (Greece)

^c G GENNIMATAS GENERAL HOSPITAL   (Greece)

Author keywords

Chemotherapy; Colorectal cancer; Prognostic factors; Survival

Indexed keywords

BEVACIZUMAB; C REACTIVE PROTEIN; CA 19-9 ANTIGEN; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; RECOMBINANT ERYTHROPOIETIN;

ADRENAL METASTASIS; ADULT; ANEMIA; ANOREXIA; ARTICLE; BLOOD TRANSFUSION; BONE METASTASIS; CANCER PAIN; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; FATIGUE; FEMALE; FEVER; HAND FOOT SYNDROME; HUMAN; HYPOALBUMINEMIA; LIVER METASTASIS; LIVER TOXICITY; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUROLOGICAL COMPLICATION; NEUTROPENIA; OVERALL SURVIVAL; PELVIS METASTASIS; PERITONEUM METASTASIS; PREDICTION; PRIORITY JOURNAL; PROBABILITY; SKIN DISEASE; SKIN METASTASIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING; WEIGHT REDUCTION;

ADULT; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MEDICAL RECORDS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 77950527311     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008.
2. Goldberg RM, Rothenberg ML, Van Cutsem E, Benson AB 3rd, Blanke CD, Diasio RB, Grothey A, Lenz HJ, Meropol NJ, Ramanathan RK, Becerra CH, Wickham R, Armstrong D and Viele C: The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist 12: 38-50, 2007.
3. Field K and Lipton L: Metastatic colorectal cancer-past, progress and future. World J Gastroenterol 13: 3806-3815, 2007.
4. Scheithauer W, Rosen H, Kornek GV, Sebesta C and Depisch D: Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 306: 752-755, 1993.
5. Folprecht G, Cunningham D, Ross P, Glimelius B, Di Costanzo F, Wils J, Scheithauer W, Rougier P, Aranda E, Hecker H and Köhne CH: Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol 75: 1330-1338, 2004.
6. Goldberg RM: Therapy for metastatic colorectal cancer. Oncologist 11: 981-987, 2006.
7. Köhne CH and Folprecht G: Current perspectives in the treatment of metastatic colorectal cancer. Ann Oncol 15 Suppl 4: iv43-53, 2004.
8. Pentheroudakis G, Fountzilas G, Kalofonos HP, Golfinopoulos V, Aravantinos G, Bafaloukos D, Papakostas P, Pectasides D, Christodoulou C, Syrigos K, Economopoulos T and Pavlidis N; Hellenic Cooperative Oncology Group: Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors. Crit Rev Oncol Hematol 66: 237-247, 2008.
9. Compton CC, Fielding LP, Burgart LJ, Conley B, Cooper HS, Hamilton SR, Hammond ME, Henson DE, Hutter RV, Nagle RB, Nielsen ML, Sargent DJ, Taylor CR, Welton M and Willett C: Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124: 979-994, 1999.
10. Sorbye H, Köhne CH, Sargent DJ and Glimelius B: Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer: a proposal for standardization of patient characteristic reporting and stratification. Ann Oncol 78: 1666-1672, 2007.
11. Kemeny N and Braun DW Jr: Prognostic factors in advanced colorectal carcinoma. Importance of lactic dehydrogenase level, performance status, and white blood cell count. Am J Med 74: 786-794, 1983.
12. Edler L, Heim ME, Quintero C, Brummer T and Queisser W: Prognostic factors of advanced colorectal cancer patients. Eur J Cancer Clin Oncol 22: 1231-1237, 1986.
13. Graf W, Glimelius B, Pâhlman L and Bergström R: Determinants of prognosis in advanced colorectal cancer. Eur J Cancer 27: 1119-1123, 1991.
14. Steinberg J, Erlichman C, Gadalla T, Fine S and Wong A: Prognostic factors in patients with metastatic colorectal cancer receiving 5-fluorouracil and folinic acid. Eur J Cancer 28A: 1817-1820, 1992.
15. Rougier P, Milan C, Lazorthes F, Fourtanier G, Partensky C, Baumel H and Faivre J: Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer. Fondation Française de Cancérologie Digestive. Br J Surg 82: 1397-1400, 1995.
16. Assersohn L, Norman A, Cunningham D, Benepal T, Ross PJ and Oates J: Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma. Br J Cancer 79: 1800-1805, 1999.
17. Massacesi C, Norman A, Price T, Hill M, Ross P and Cunningham D: A clinical nomogram for predicting long-term survival in advanced colorectal cancer. Eur J Cancer 36: 2044-2052, 2000.
18. Köhne CH, Cunningham D, Di CF, Glimelius B, Blijham G, Aranda E, Scheithauer W, Rougier P, Palmer M, Wils J, Baron B, Pignatti F, Schöffski P, Micheel S and Hecker H: Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 13: 308-317, 2002.
19. Yuste AL, Aparicio J, Segura A, López-Tendero P, Gironés R, Pérez-Fidalgo JA, Díaz R and Calderero V: Analysis of clinical prognostic factors for survival and time to progression in patients with metastatic colorectal cancer treated with 5-fluorouracil-based chemotherapy. Clin Colorectal Cancer 2: 231-234, 2003.
20. Mitry E, Douillard JY, Van Cutsem E, Cunningham D, Magherini E, Mery-Mignard D, Awad L and Rougier P: Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials. Ann Oncol 15: 1013-1017, 2004.
21. Stelzner S, Hellmich G, Koch R and Ludwig K: Factors predicting survival in stage IV colorectal carcinoma patients after palliative treatment: a multivariate analysis. J Surg Oncol 89: 211-217, 2005.
22. Díaz R, Aparicio J, Gironés R, Molina J, Palomar L, Segura A and Montalar J: Analysis of prognostic factors and applicability of Kohne's prognostic groups in patients with metastatic colorectal cancer treated with first-line irinotecan or oxaliplatin-based chemotherapy. Clin Colorectal Cancer 5: 197-202, 2005.
23. Suenaga M, Mizunuma N, Shouji D, Shinozaki E, Matsusaka S, Chin K, Oya M, Yamaguchi T, Muto T and Hatake K: Modified irinotecan plus bolus 5-fluorouracil/L-leucovorin for metastatic colorectal cancer at a single institution in Japan. J Gastroenterol 43: 842-848, 2008.
24. Glimelius B, Linné T, Hoffman K, Larsson L, Svensson JH, Näsman P, Svensson B and Helmers C: Epoetin beta in the treatment of anemia in patients with advanced gastrointestinal cancer. J Clin Oncol 16: 434-440, 1998.
25. Chu E, Einhorn LH and Lefebvre P: Clinical benefits of once-weekly epoetin alfa in anemic patients with colorectal cancer receiving chemotherapy. J Support Oncol 4: 243-250, 2006.
26. Lahr CJ, Soong SJ, Cloud G, Smith JW, Urist MM and Balch CM: A multifactorial analysis of prognostic factors in patients with liver metastases from colorectal carcinoma. J Clin Oncol 1: 720-726, 1983.
27. Lenz HJ, Van Cutsem E, Khambata-Ford S, Mayer RJ, Gold P, Stella P, Mirtsching B, Cohn AL, Pippas AW, Azarnia N, Tsuchihashi Z, Mauro DJ and Rowinsky EK: Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 24: 4914-4921, 2006.
28. Nozoe T, Matsumata T, Kitamura M and Sugimachi K: Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg 176: 335-338, 1998.
29. McMillan DC, Wotherspoon HA, Fearon KC, Sturgeon C, Cooke TG and McArdle CS: A prospective study of tumor recurrence and the acute-phase response after apparently curative colorectal cancer surgery. Am J Surg 170: 319-322, 1995.
30. Wigmore SJ, McMahon AJ, Sturgeon CM and Fearon KC: Acute-phase protein response, survival and tumour recurrence in patients with colorectal cancer. Br J Surg 88: 255-260, 2001.
31. Chung YC and Chang YF: Serum C-reactive protein correlates with survival in colorectal cancer patients but is not an independent prognostic indicator. J Surg Oncol 83: 222-226, 2003.
32. Yun HR, Lee WY, Lee WS, Cho YB, Yun SH and Chun HK: The prognostic factors of stage IV colorectal cancer and assessment of proper treatment according to the patient's status. Int J Colorectal Dis 22: 1301-1310, 2007.
33. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L and Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355: 1041-1047, 2000.